

Report 2021-22

Membership in PPWG is slowly increasing with currently 122 members.

The budget of the PPWG is in good standing. We awarded 500 Euros for the best pulmonary pathology poster and 300 Euros for the best e-poster presented at the virtual ESP congress 2021, which should have taken place in Gothenburg. The following posters were awarded:

<u>Poster</u>: Potential role of Tenascin C (TNC) in human lung adenocarcinoma progression M. Schlensog^{*}, A. Ruehlmann, L. Haeberle, A. Becher, W. Goering, J. Limberg, W.T. Knoefel, I. Esposito. *Institute of Pathology, Heinrich-Heine University and University Hospital Duesseldorf, Germany.

<u>E-poster</u>: Multicentre evaluation of the Idylla[™] GeneFusion cartridge in lung cancer, A. Lupo, Department of pathology, Hôpital Cochin, AP-HP, Université de Paris, France. At the ESP 2022 conference in Basel, we awarded a poster presentation of a retrospective study focusing on the prognostic implications of STAS (tumor spread through air spaces) in lung adenocarcinoma, by authors Samuel Lopez-Munoz, L. Gutierrez-Sainz, I. Losantos-Garcia, P. Cruz-Castellanos, O. Higuera, J. de Castro-Carpeno, M.I.Esteban-Rodriguez from Department of Pathology, University Hospital La Paz, Madrid, Spain.

During the last years, the activity of our group has been challenged by the pandemic. Both ESP congresses, Gothenburg virtual and Basel live, were well attended, featuring an excellent scientific program. An undisputable add on value was the availability of recorded sessions that could be attended for a limited period of time after the congress. Several industry symposia focused on lung carcinoma predictive biomarker testing. Invited speakers were well known pulmonary pathologist. Last year we organized the webinar "Update on lung cancer biomarker testing". Three lecturers, Lynette Scholl, Albert Stenzinger and Paul Hofman, discussed Her2 and EGFR exon 20 mutations, EGFR testing in early stages and patterns of resistance to TKIs.

We were involved in updating the set of questions for the ESP Pathology progress test. Together with Luka Brcic, the liaison person, we prepared a set of 60 questions.

We prepared the program for the new EScoP course, which is scheduled for June 2023 in Bucharest. It is planned to repeat the course 4x in different places across Europe within the next 8 years period. The three-day course program will cover the entire thoracic pathology (lung, pleura, thymus, and mediastinum). Neoplastic and non-neoplastic diseases will be presented in short lectures, slide seminars and using videomicroscopy. The target audience are young pathologists, residents and colleagues starting to work in this field.

The virtual preceptorship initiative integrating novel NSCLC biomarkers in routine pathology practice has started, which is aimed at optimal diagnostic approaches, predictive biomarker testing, guidelines and liquid biopsy.

A high-quality program was prepared for the annual ESP congress 2023 in Dublin. The proposal for six sessions was accepted: We will start with a symposium on thoracic and digestive system neuroendocrine neoplasms: similarities and differences. This session is jointly prepared by the Thymic and Mediastinal Pathology WG, Digestive diseases WG and our WG. The topic of digital pathology solutions in pulmonary pathology will be presented during a long course session jointly organized by the Digital Pathology WG and our WG. We will continue the established good collaboration with the Molecular Pathology WG in the short course session "when liquid biopsy meets the pathologists". Diagnostic challenges in pulmonary vascular pathology will be presented during the joint short course session on intriguing interstitial lung diseases, and finally yet importantly, a videomicroscopy session focused on mesothelial proliferations including differential diagnostic challenges.

After the ECP Basel, the virtual business meeting was held in late December. During the virtual business meeting, the chair of the PPWG Izidor Kern gave a summary of the PPWG activity during the last years. A membership list is regularly updated. The new chair and co-chair of the WG were elected and introduced: Paul Hofman, the new chair, and Sabina Berezowska, the new co-chair. We encouraged members to participate in external quality assurance schemes (PD-L1 and lung cancer molecular testing). Plans for the scientific and educational activities in the upcoming year were briefly presented. Any initiatives by members and other colleagues interested in pulmonary pathology are welcome.

Thank you for reading this report and for your support of the PPWG. Please feel free to contact us for any questions or suggestions.

Izidor Kern, Chair of PPWG

Paul Hofman, Co-chair of PPWG